4-{2-[2-Methyl-1-(2-methyl-propane-2-sulfinylamino)-propyl]-4-trifluoromethyl-phenyl}-piperazine-1-carboxylic acid tert-butyl ester | 910300-23-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 4-{2-[2-Methyl-1-(2-methyl-propane-2-sulfinylamino)-propyl]-4-trifluoromethyl-phenyl}-piperazine-1-carboxylic acid tert-butyl ester
• 英文别名: Tert-butyl 4-[2-[1-(tert-butylsulfinylamino)-2-methylpropyl]-4-(trifluoromethyl)phenyl]piperazine-1-carboxylate
• CAS: 910300-23-1
• 化学式: C₂₄H₃₈F₃N₃O₃S
• 分子量: 505.645
• InChiKey: UNVCXKWRCAKOMB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  34
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  81.1
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  4-{2-[2-Methyl-1-(2-methyl-propane-2-sulfinylamino)-propyl]-4-trifluoromethyl-phenyl}-piperazine-1-carboxylic acid tert-butyl ester 在 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  Arylpropionylpiperazines as antagonists of the human melanocortin-4 receptor

  摘要：

  A series of 3-arylpropionylpiperazines were synthesized as antagonists of the melanocortin-4 receptor. Their potency was found to be increased by replacing the alpha-methyl substituent of the initial lead 11 with a larger s-Bu or i-Bu group. Further potency enhancement was observed when a glycine or beta-alanine was incorporated onto the benzylamine. Some compounds demonstrated good potency, moderate selectivity, and oral bioavailability. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.05.088
• 作为产物：
  描述：

  4-(2-甲酰基-4-(三氟甲基)苯基)哌嗪-1-羧酸叔丁酯 在 titanium(IV) tetraethanolate 、 三甲基铝 作用下， 以 四氢呋喃 为溶剂， 生成 4-{2-[2-Methyl-1-(2-methyl-propane-2-sulfinylamino)-propyl]-4-trifluoromethyl-phenyl}-piperazine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Arylpropionylpiperazines as antagonists of the human melanocortin-4 receptor

  摘要：

  A series of 3-arylpropionylpiperazines were synthesized as antagonists of the melanocortin-4 receptor. Their potency was found to be increased by replacing the alpha-methyl substituent of the initial lead 11 with a larger s-Bu or i-Bu group. Further potency enhancement was observed when a glycine or beta-alanine was incorporated onto the benzylamine. Some compounds demonstrated good potency, moderate selectivity, and oral bioavailability. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.05.088